Preventative Cardiology

  • DAL-302: A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent AcuteCoronary Syndrome (ACS). Sumanth Prabu, MD. DalCor Pharmaceuticals
    CURRENTLY ENROLLING
    view on clinicaltrials.org
  • Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics (PopPK) Profile of ABP-745 in Patients with Atherosclerosis. Farhan Katchi, MD. Atom Therapeutics Co., Ltd.
    CURRENTLY ENROLLING
    view on clinicaltrials.org
  • KPL-387-C211:  A Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants with Recurrent Pericarditis. Amanda Verma, M.D. Kiniksa Pharmaceuticals, GmBH.
    CURRENTLY ENROLLING
    view on clinicaltrials.org
  • KPL-387-C212: A Phase 2 Posology Study with Long-Term Extension in Participants with Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy from Standard Therapies. Amanda Verma, M.D. Kiniska Pharmaceuticals, GmBH.
    view on clinicaltrials.org
  • Plaque Characterization using Photon-Counting CT Angiography: A comparison study using conventional energy integrating detector CT and coronary angiography with intravascular imaging. Farhan Katchi, MD. Siemen’s Medical Solutions Inc.
  • PLAQURACY: Coronary Plaque Quantification by Photon-Counting Detector CT: Accuracy and Reproducibility. Farhan Katchi, MD, Siemens Corporation.
    CURRENTLY ENROLLING
  • PROMPT-LIPID: PRagmatic Trial Of Messaging to Providers about Treatment of HyperLIPIDemia: The PROMPT-Lipid Multicenter Registry Study. Thomas Maddox, M.D. Yale University.
    view on clinicaltrials.org
  • PURIFY-TIMI 8A: Randomized, Multicenter, Double-Blind, Parallel, Placebo-controlled Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of YN001 in Adults with Coronary Atherosclerosis. Farhan Katchi, M.D.  Beijing Inno Medicine Co. Ltd.
    CURRENTLY ENROLLING
    view on clinicaltrials.org
  • TRANSFORM A: Randomized comparison of Cleerly Coronary Artery Disease Stage-Based Care using Coronary CT angiography vs Risk Factor-Based Care for Primary Prevention of Cardiovascular Events. Farhan Katchi, MD.  Cleerly, Inc. 
    CURRENTLY ENROLLING
    view on clinicaltrials.org
    NCT06112418
  • VICTORION-1-PREVENT: A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients. Farhan Katchi, MD. Novartis.
    view on clinicaltrials.org
  • VICTORION-INCLUSION: Evaluating INClisiran as a soLUtion to improve LDL-C management and cloSe care gaps in an Inclusive ASCVD and ASCVD risk equivalent populatiON(V). Dr. Farhan Katchi, MD. Duke University.
    CLOSED TO ENROLLMENT
    view on clinicaltrials.org